RNS Announcements

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a new commercial partnership with Mexico based raw materials and ingredients specialist Raff.

Founded in 1999, Raff is a distributor of raw materials and value-added ingredients, with a particular focus on the dairy and nutraceutical sectors. Backed by a highly trained technical team, Raff specialises in the use and application of lactic and probiotic cultures, rennet, enzymes and preservatives.

Mexico has a population of 131 million people, with cardiovascular disease the single largest killer, accounting for nearly 24% of all deaths. Moreover, it is estimated that around 3.6 million people die in Mexico every year from high cholesterol. The movement from ‘cure’ towards ‘prevention’ provides a strong backdrop for the fast-growing supplement market, which should lead to a good sales opportunity for ProBiotix.

The five-year agreement enables Raff to act in partnership with ProBiotix, as the exclusive distributor of LP_LDL® to be used as an ingredient for the local manufacturing of finished products. The launch is planned for the first half of 2025, with commercial sales expected in late 2025/early 2026.

Steen Andersen, CEO of ProBiotix, commented: “After lengthy discussions we are delighted to announce our partnership with Raff and firmly believe that they share our ethos – to develop innovative products to help enrich individuals with healthier lives.

“The cardiovascular drug market in Mexico is estimated to be worth $2.2 billion this year, and provides a huge latent opportunity. With an ageing population, we believe Mexico provides a highly attractive market for ProBiotix to target.”

Rafael Gonzalez, Commercial Director of Raff, added: “As an already well established probiotics supplier in the Mexican market through our relationship with Italy based Sacco Systems, having the opportunity to partner with ProBiotix Health, being a pioneer within probiotics and cardiometabolic health, is extremely exciting for us.

“We welcome the opportunity to expand our portfolio with a unique well documented precision biotic like LP_LDL®. It is our belief that LP_LDL®  fills an untapped potential in the fast growing Mexican supplement market, and that the product sits well with our already strong position in the sector.”

For further information, please contact:

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a new commercial partnership with Mexico based raw materials and ingredients specialist Raff.

Founded in 1999, Raff is a distributor of raw materials and value-added ingredients, with a particular focus on the dairy and nutraceutical sectors. Backed by a highly trained technical team, Raff specialises in the use and application of lactic and probiotic cultures, rennet, enzymes and preservatives.

Mexico has a population of 131 million people, with cardiovascular disease the single largest killer, accounting for nearly 24% of all deaths. Moreover, it is estimated that around 3.6 million people die in Mexico every year from high cholesterol. The movement from ‘cure’ towards ‘prevention’ provides a strong backdrop for the fast-growing supplement market, which should lead to a good sales opportunity for ProBiotix.

The five-year agreement enables Raff to act in partnership with ProBiotix, as the exclusive distributor of LP_LDL® to be used as an ingredient for the local manufacturing of finished products. The launch is planned for the first half of 2025, with commercial sales expected in late 2025/early 2026.

Steen Andersen, CEO of ProBiotix, commented: “After lengthy discussions we are delighted to announce our partnership with Raff and firmly believe that they share our ethos – to develop innovative products to help enrich individuals with healthier lives.

“The cardiovascular drug market in Mexico is estimated to be worth $2.2 billion this year, and provides a huge latent opportunity. With an ageing population, we believe Mexico provides a highly attractive market for ProBiotix to target.”

Rafael Gonzalez, Commercial Director of Raff, added: “As an already well established probiotics supplier in the Mexican market through our relationship with Italy based Sacco Systems, having the opportunity to partner with ProBiotix Health, being a pioneer within probiotics and cardiometabolic health, is extremely exciting for us.

“We welcome the opportunity to expand our portfolio with a unique well documented precision biotic like LP_LDL®. It is our belief that LP_LDL®  fills an untapped potential in the fast growing Mexican supplement market, and that the product sits well with our already strong position in the sector.”

For further information, please contact:

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a new commercial partnership with Mexico based raw materials and ingredients specialist Raff.

Founded in 1999, Raff is a distributor of raw materials and value-added ingredients, with a particular focus on the dairy and nutraceutical sectors. Backed by a highly trained technical team, Raff specialises in the use and application of lactic and probiotic cultures, rennet, enzymes and preservatives.

Mexico has a population of 131 million people, with cardiovascular disease the single largest killer, accounting for nearly 24% of all deaths. Moreover, it is estimated that around 3.6 million people die in Mexico every year from high cholesterol. The movement from ‘cure’ towards ‘prevention’ provides a strong backdrop for the fast-growing supplement market, which should lead to a good sales opportunity for ProBiotix.

The five-year agreement enables Raff to act in partnership with ProBiotix, as the exclusive distributor of LP_LDL® to be used as an ingredient for the local manufacturing of finished products. The launch is planned for the first half of 2025, with commercial sales expected in late 2025/early 2026.

Steen Andersen, CEO of ProBiotix, commented: “After lengthy discussions we are delighted to announce our partnership with Raff and firmly believe that they share our ethos – to develop innovative products to help enrich individuals with healthier lives.

“The cardiovascular drug market in Mexico is estimated to be worth $2.2 billion this year, and provides a huge latent opportunity. With an ageing population, we believe Mexico provides a highly attractive market for ProBiotix to target.”

Rafael Gonzalez, Commercial Director of Raff, added: “As an already well established probiotics supplier in the Mexican market through our relationship with Italy based Sacco Systems, having the opportunity to partner with ProBiotix Health, being a pioneer within probiotics and cardiometabolic health, is extremely exciting for us.

“We welcome the opportunity to expand our portfolio with a unique well documented precision biotic like LP_LDL®. It is our belief that LP_LDL®  fills an untapped potential in the fast growing Mexican supplement market, and that the product sits well with our already strong position in the sector.”

For further information, please contact: